Floatz logo

Idp-121

Double Hit Lymphoma

IDP Discovery Pharma S.L.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Double Hit Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Yazeed Sawalha
Phase 2B
(+)-VINCRISTINE
Patrick C. Johnson, MD
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2B
Venetoclax
National Cancer Institute (NCI)
Phase 2B
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2B

View all 40 →

Same molecule, other indications

Idp-121 is also rated in:

diffuse large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →